Insulin to the rescue: a review of recent reports on insulin treatment in emergencies and poisonings
DOI:
https://doi.org/10.56782/pps.362Keywords:
Emergency medicine, HIET, insulin, poisoning, toxicologyAbstract
Insulin, produced by pancreatic β-cells, is a critical anabolic hormone that plays a pivotal role in the regulation of carbohydrate metabolism. Dysregulation of insulin secretion can pose significant threats to health and life, underscoring the importance of its discovery. The introduction of insulin as a therapeutic agent revolutionized diabetes management. Currently, human insulin and its analogs, manufactured through advanced genetic engineering techniques, are widely used. Despite more than a century of clinical use, efforts to improve insulin formulations continue, aiming to enhance patient comfort and reduce the frequency of injections. Insulin is also employed in the management of acute conditions, such as diabetic ketoacidosis and hyperglycemic hyperosmolar state, where intravenous administration is used to lower blood glucose levels effectively. Additionally, insulin is effective in the treatment of hyperkalemia and in cases of poisoning with calcium channel blockers and β-receptor antagonists. In these scenarios, insulin has the highest therapeutic recommendation class. High-dose insulin euglycemic therapy (HIET) is implemented using doses of approximately 1 IU/kg body weight, regardless of patient age, with careful maintenance of euglycemia. HIET is also considered in cases of poisoning with metal phosphides and refractory shock. Positive outcomes have been reported in the literature for patients treated with high-dose insulin for caffeine poisoning and venlafaxine toxicity. These isolated reports highlight the need for further research and development of insulin therapy in acute medical conditions, potentially expanding its applications beyond traditional indications.
Downloads
References
1. Sędzikowska, A.; Szablewski, L. Insulin and Insulin Resistance in Alzheimer's Disease. Int. J. Mol. Sci. 2021, 22(18), Art. No: 9987. DOI: 10.3390/ijms22189987 DOI: https://doi.org/10.3390/ijms22189987
2. Tokarz, V.L.; MacDonald, P.E.; Klip, A. The cell biology of systemic insulin function. J. Cell Biol. 2018, 217(7), 2273-2289. DOI: 10.1083/jcb.201802095 DOI: https://doi.org/10.1083/jcb.201802095
3. Hwang, H.G.; Kim, K.J.; Lee, S.H.; Kim, C.K.; Min, C.K.; Yun, J.M.; Lee S.U.; Son, Y.J. Recombinant Glargine Insulin Production Process Using Escherichia coli. J. Microbiol. Biotechnol. 2016, 26(10), 1781-1789. DOI: 10.4014/jmb.1602.02053 DOI: https://doi.org/10.4014/jmb.1602.02053
4. Mathieu, C.; Martens, P.J.; Vangoitsenhoven, R. One hundred years of insulin therapy. Nat. Rev. Endocrinol. 2021, 17(12), 715-725. DOI: 10.1038/s41574-021-00542-w DOI: https://doi.org/10.1038/s41574-021-00542-w
5. Heise, T. The future of insulin therapy. Diabetes Res. Clin. Pract. 2021, 175, Art. No: 108820. DOI: 10.1016/j.diabres.2021.108820 DOI: https://doi.org/10.1016/j.diabres.2021.108820
6. Chen, W.; Cai, W.; Hoover, B.; Kahn, C.R. Insulin action in the brain: cell types, circuits, and diseases. Trends Neurosci. 2022, 45(5), 384-400. DOI: 10.1016/j.tins.2022.03.001 DOI: https://doi.org/10.1016/j.tins.2022.03.001
7. Akhtar, A.; Sah, S.P. Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer's disease. Neurochem. Int. 2020, 135, Art. No: 104707. DOI: 10.1016/j.neuint.2020.104707 DOI: https://doi.org/10.1016/j.neuint.2020.104707
8. Tumminia, A.; Vinciguerra, F.; Parisi, M.; Frittitta, L. Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications. Int. J. Mol. Sci. 2018, 19(11), 3306. DOI: 10.3390/ijms19113306 DOI: https://doi.org/10.3390/ijms19113306
9. Biosa, A.; Outeiro, T.F.; Bubacco, L.; Bisaglia, M. Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View. Mol. Neurobiol. 2018, 55(11), 8754-8763. DOI: 10.1007/s12035-018-1025-9 DOI: https://doi.org/10.1007/s12035-018-1025-9
10. Hallschmid, M. Intranasal Insulin for Alzheimer's Disease. CNS Drugs 2021, 35(1), 21-37. DOI: 10.1007/s40263-020-00781-x DOI: https://doi.org/10.1007/s40263-020-00781-x
11. Araszkiewicz, A.; Bandurska-Stankiewicz, E. et al. Zalecenia kliniczne dotyczące postępowania u osób z cukrzycą 2023 - Stanowisko Polskiego Towarzystwa Diabetologicznego. Curr. Top. Diabetes 2023, 3(1), 1-140
12. Yan, J.W.; Slim, A.; Van Aarsen, K.; Choi, Y.H.; Byrne, C.; Poonai, N.; Collins, H.; Clemens, K.K. Balanced crystalloids (RInger's lactate) versus normal Saline in adults with diabetic Ketoacidosis in the Emergency Department (BRISK-ED): a protocol for a pilot randomized controlled trial. Pilot Feasibility Stud. 2023, 9(1), Art. No: 121. DOI: 10.1186/s40814-023-01356-5 DOI: https://doi.org/10.1186/s40814-023-01356-5
13. Dunn, B. K.; Coore, H.; Bongu, N.; Brewer, K. L.; Kumar, D.; Malur, A.; Alkhalisy, H. Treatment Challenges and Controversies in the Management of Critically Ill Diabetic Ketoacidosis (DKA) Patients in Intensive Care Units. Cureus 2024, 16(9), Art. No: e68785. DOI: 10.7759/cureus.68785 DOI: https://doi.org/10.7759/cureus.68785
14. Catahay, J. A.; Polintan, E. T.; Casimiro, M.; Notarte, K. I.; Velasco, J. V.; Ver, A. T.; Pastrana, A.; Macaranas, I.; Patarroyo-Aponte, G.; Lo, K. B. Balanced Electrolyte Solutions Versus Isotonic Saline in Adult Patients With Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis. Heart Lung 2022, 54, 74–79. DOI: 10.1016/j.hrtlng.2022.03.014 DOI: https://doi.org/10.1016/j.hrtlng.2022.03.014
15. Thammakosol, K.; Sriphrapradang, C. Effectiveness and Safety of Early Insulin Glargine Administration in Combination With Continuous Intravenous Insulin Infusion in Management of Diabetic Ketoacidosis: A Randomized Controlled Trial. Diabetes, Obes. Metab. 2023, 25(3), 815-822. DOI: 10.1111/dom.14929 DOI: https://doi.org/10.1111/dom.14929
16. Gilbert, B. W.; Murray, D. S.; Cox, T. R.; He, J.; Wenski, A. M.; Qualls, K. E. What Are We Waiting For? A Review of Early Basal Insulin Therapy in Diabetic Ketoacidosis Management. Am. J. Emerg. Med. 2023, 72, 147–150. DOI: 10.1016/j.ajem.2023.07.049 DOI: https://doi.org/10.1016/j.ajem.2023.07.049
17. Dhatariya, K. K. The management of diabetic ketoacidosis in adults—An updated guideline from the Joint British Diabetes Society for Inpatient Care. Diabet. Med. 2022, 39(6), Art. No: e14788. DOI: 10.1111/dme.14788 DOI: https://doi.org/10.1111/dme.14788
18. Lavonas, E. J.; Akpunonu, P. D.; Arens, A. M.; Babu, K. M.; Cao, D.; Hoffman, R. S.; Hoyte, C. O.; Mazer-Amirshahi, M. E.; Stolbach, A.; St-Onge, M.; i in. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2023, 148(16), 149-184. DOI: 10.1161/cir.0000000000001161 DOI: https://doi.org/10.1161/CIR.0000000000001161
19. Alshaya, O. A.; Alhamed, A.; Althewaibi, S.; Fetyani, L.; Alshehri, S.; Alnashmi, F.; Alharbi, S.; Alrashed, M.; Alqifari, S. F.; Alshaya, A. I. Calcium Channel Blocker Toxicity: A Practical Approach. J. Multidiscip. Healthc. 2022, 15, 1851–1862. DOI: 10.2147/jmdh.s374887 DOI: https://doi.org/10.2147/JMDH.S374887
20. Lott, C.; Truhlář, A.; Alfonzo, A.; Barelli, A.; González-Salvado, V.; Hinkelbein, J.; Nolan, J. P.; Paal, P.; Perkins, G. D.; Thies, K.-C.; i in. Corrigendum to “European Resuscitation Council Guidelines 2021: Cardiac Arrest in Special Circumstances” [Resuscitation 161 (2021) 152–219]. Resuscitation 2021, 167, 91–92. DOI: 10.1016/j.resuscitation.2021.08.012 DOI: https://doi.org/10.1016/j.resuscitation.2021.08.012
21. Cole, J.B.; Arens, A.M.; Laes, J.R.; Klein, L.R.; Bangh, S.A.; Olives, T.D. High dose insulin for beta-blocker and calcium channel-blocker poisoning. Am. J. Emerg. Med. 2018, 36(10), Art. No: 1817-1824. DOI: 10.1016/j.ajem.2018.02.004 DOI: https://doi.org/10.1016/j.ajem.2018.02.004
22. Lheureux, P.E.; Zahir, S.; Gris, M.; Derrey, A.S.; Penaloza, A. Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers. Crit Care. 2006, 10(3), Art. No: 212. DOI: 10.1186/cc4938 DOI: https://doi.org/10.1186/cc4938
23. Schult, R. F.; Nacca, N.; Grannell, T. L.; Jorgensen, R. M.; Acquisto, N. M. Evaluation of high-dose insulin/euglycemia therapy for suspected β-blocker or calcium channel blocker overdose following guideline implementation. Am. J. Heal. Pharm. 2021, 79 (7), 547–555. DOI: 10.1093/ajhp/zxab439 DOI: https://doi.org/10.1093/ajhp/zxab439
24. Engebretsen, K. M.; Kaczmarek, K. M.; Morgan, J.; Holger, J. S. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin. Toxicol. 2011, 49(4), 277–283. DOI: 10.3109/15563650.2011.582471 DOI: https://doi.org/10.3109/15563650.2011.582471
25. Rotella, J.-A.; Greene, S. L.; Koutsogiannis, Z.; Graudins, A.; Hung Leang, Y.; Kuan, K.; Baxter, H.; Bourke, E.; Wong, A. Treatment for beta-blocker poisoning: a systematic review. Clin. Toxicol. 2020, 58(10), 943–983. DOI: 10.1080/15563650.2020.1752918 DOI: https://doi.org/10.1080/15563650.2020.1752918
26. Goldfine, C. E.; Troger, A.; Erickson, T. B.; Chai, P. R. Beta blocker and calcium channel blocker toxicity: Current evidence on evaluation and management. Eur. Heart J. Acute Cardiovasc. Care 2023, 13(2), 247-253. DOI: 10.1093/ehjacc/zuad138 DOI: https://doi.org/10.1093/ehjacc/zuad138
27. Greene, S. L.; Gawarammana, I.; Wood, D. M.; Jones, A. L.; Dargan, P. I. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. 2007, 33(11), 2019–2024. DOI: 10.1007/s00134-007-0768-y DOI: https://doi.org/10.1007/s00134-007-0768-y
28. Jessen, M. K.; Andersen, L. W.; Djakow, J.; Chong, N. K.; Stankovic, N.; Staehr, C.; Vammen, L.; Petersen, A. H.; Johannsen, C. M.; Eggertsen, M. A.; et al. Pharmacological Interventions for the Acute Treatment of Hyperkalaemia: A Systematic Review and Meta-analysis. Resuscitation 2025, 208, Art. No: 110489. DOI: 10.1016/j.resuscitation.2025.110489 DOI: https://doi.org/10.1016/j.resuscitation.2025.110489
29. LaRue, H. A.; Peksa, G. D.; Shah, S. C. A Comparison of Insulin Doses for the Treatment of Hyperkalemia in Patients with Renal Insufficiency. Pharmacotherapy 2017, 37(12), 1516–1522. DOI: 10.1002/phar.2038 DOI: https://doi.org/10.1002/phar.2038
30. Garcia, J.; Pintens, M.; Morris, A.; Takamoto, P.; Baumgartner, L.; Tasaka, C. L. Reduced Versus Conventional Dose Insulin for Hyperkalemia Treatment. J. Pharm. Pract. 2018, 33(3), 262–266. DOI: 10.1177/0897190018799220 DOI: https://doi.org/10.1177/0897190018799220
31. Wheeler, D. T.; Schafers, S. J.; Horwedel, T. A.; Deal, E. N.; Tobin, G. S. Weight-based insulin dosing for acute hyperkalemia results in less hypoglycemia. J. Hosp. Med. 2016, 11(5), 355–357. DOI: 10.1002/jhm.2545 DOI: https://doi.org/10.1002/jhm.2545
32. Pierce, D. A.; Russell, G.; Pirkle, J. L. Incidence of Hypoglycemia in Patients With Low eGFR Treated With Insulin and Dextrose for Hyperkalemia. Ann. Pharmacother. 2015, 49(12), 1322–1326. DOI: 10.1177/1060028015607559 DOI: https://doi.org/10.1177/1060028015607559
33. Główny Inspektorat Sanitarny, Postępowanie w ostrych zatruciach fosforowodorem. Available online: https://www.gov.pl/web/gis/postepowanie-w-ostrych-zatruciach-fosforowodorem (accessed on 12.01.2025)
34. Shukla, R.; Lamichhane, K.; Pandey, D.; Gupta, C. K.; Shukla, S. Insulin in aluminum phosphide poisoning: A systematic review of the current literature. Medicine 2024, 103(42), Art. No: e40066. DOI: 10.1097/md.0000000000040066 DOI: https://doi.org/10.1097/MD.0000000000040066
35. Sedaghattalab, M. Treatment of critical aluminum phosphide (rice tablet) poisoning with high-dose insulin: a case report. J. Med. Case Rep. 2022, 16 (1), Art. No: 192. DOI: 10.1186/s13256-022-03425-4 DOI: https://doi.org/10.1186/s13256-022-03425-4
36. Hensher, C.; Vogel, J. High-Dose Insulin Euglycemic Therapy in the Treatment of a Massive Caffeine Overdose. Chest 2020, 157(5), e145-e149. DOI: 10.1016/j.chest.2019.11.030 DOI: https://doi.org/10.1016/j.chest.2019.11.030
37. Batista, M.; Dugernier, T.; Simon, M.; Haufroid, V.; Capron, A.; Fonseca, S.; Bonbled, F.; Hantson, P. The spectrum of acute heart failure after venlafaxine overdose. Clin. Toxicol. 2013, 51(2), 92–95. DOI: 10.3109/15563650.2012.763133 DOI: https://doi.org/10.3109/15563650.2012.763133
38. Stefani, M.; Roberts, D. M.; Brett, J. High-dose insulin euglycemic therapy to treat cardiomyopathy associated with massive venlafaxine overdose. Clin. Toxicol. 2019, 58(4), 299–300. DOI: 10.1080/15563650.2019.1638930 DOI: https://doi.org/10.1080/15563650.2019.1638930
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Dominika Mularska, Oskar Fogiel, Kinga Kocur, Małgorzata Rak, Natalia Pawlas
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
